Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast has disclosed a change in the securities held by Chief Executive Dr Silviu Itescu, reporting the issue of 2,025,600 additional options following shareholder approval at the company’s 2025 annual general meeting. The transaction leaves his ordinary shareholding unchanged at 78,958,928 shares, while increasing his total options to 18,475,158, and was undertaken with no cash consideration, reflecting an equity-based component of executive remuneration rather than on-market trading.
The notification indicates that the options grant was approved as part of the company’s formal governance processes and did not occur during a closed trading period, suggesting adherence to ASX listing rules and internal trading policies. For investors, the increased option position further aligns the chief executive’s incentives with long-term shareholder value, while not immediately altering the free float or cash position, although it may have a modest dilutive effect if exercised in future.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biopharmaceutical company focused on developing allogeneic cellular medicines for inflammatory diseases, cardiovascular conditions, and other serious illnesses. The company is listed on the ASX and regularly reports changes in directors’ interests in its securities in accordance with Australian corporate governance and disclosure requirements.
Average Trading Volume: 3,990,037
Technical Sentiment Signal: Hold
Current Market Cap: A$2.67B
See more data about MSB stock on TipRanks’ Stock Analysis page.